PMID- 24846511
OWN - NLM
STAT- MEDLINE
DCOM- 20160802
LR  - 20181202
IS  - 1898-018X (Electronic)
IS  - 1898-018X (Linking)
VI  - 22
IP  - 1
DP  - 2015
TI  - Assessment of sustained effects of levosimendan and dobutamine on left 
      ventricular systolic functions by using novel tissue Doppler derived indices in 
      patients with advanced heart failure.
PG  - 87-93
LID - 10.5603/CJ.a2014.0044 [doi]
AB  - BACKGROUND: Previous studies comparing levosimendan vs. dobutamine have revealed 
      that levosimendan is better in relieving symptoms. Echocardiographic studies have 
      been done using second measurements immediately following a dobutamine infusion 
      or while it was still being administered. The aim of our study was assessment of 
      sustained effects of 24 h levosimendan and dobutamine infusions on left 
      ventricular systolic functions. METHODS: A total of 61 patients with acutely 
      decompensated heart failure with New York Heart Association (NYHA) class III or 
      IV symptoms were randomized to receive either levosimendan or dobutamine 2:1 in 
      an open label fashion. Before and 5 days after the initiation of infusions, 
      functional class was assessed, N-terminal prohormone of B-type natriuretic 
      peptide (NT-proBNP) levels and left ventricular ejection fraction (LVEF), mitral 
      inflow peak E and A wave velocity, and E/A ratios were measured; using tissue 
      Doppler imaging, isovolumic myocardial acceleration (IVA), peak myocardial 
      velocity during isovolumic contraction (IVV), peak systolic velocity during 
      ejection period (Sa), early (E') and late (A') diastolic velocities, and E'/A' 
      and E/E' ratios were measured. RESULTS: The NYHA class improved in both groups, 
      but improvements were prominent in the levosimendan group. NT-proBNP levels were 
      significantly reduced in the levosimendan group. Improvements in LVEF and 
      diastolic indices were significant in the levosimendan group. Tissue 
      Doppler-derived systolic indices of IVV and IVA increased significantly in the 
      levosimendan group. CONCLUSIONS: Improvements in left ventricular systolic and 
      diastolic functions continue after a levosimendan infusion.
FAU - Oner, Ender
AU  - Oner E
AD  - Department of Cardiology, Istanbul Mehmet Akif Er soy Thoracic and Car 
      diovascular Surgery Training and Research Hospital, Istanbul, Turkey. 
      enderoner7@gmail.com.
FAU - Erturk, Mehmet
AU  - Erturk M
FAU - Birant, Ali
AU  - Birant A
FAU - Kurtar Mansiroglu, Asli
AU  - Kurtar Mansiroglu A
FAU - Akturk, Ibrahim Faruk
AU  - Akturk IF
FAU - Karakurt, Huseyin
AU  - Karakurt H
FAU - Yalcin, Ahmet Arif
AU  - Yalcin AA
FAU - Uzun, Fatih
AU  - Uzun F
FAU - Somuncu, Mustafa Umut
AU  - Somuncu MU
FAU - Yildirim, Aydin
AU  - Yildirim A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140520
PL  - Poland
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
RN  - 0 (Biomarkers)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Peptide Fragments)
RN  - 0 (Pyridazines)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 349552KRHK (Simendan)
RN  - 3S12J47372 (Dobutamine)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiotonic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Dobutamine/administration & dosage/adverse effects/*therapeutic use
MH  - *Echocardiography, Doppler
MH  - Female
MH  - Heart Failure/blood/*diagnostic imaging/*drug therapy/physiopathology
MH  - Humans
MH  - Hydrazones/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Predictive Value of Tests
MH  - Pyridazines/administration & dosage/adverse effects/*therapeutic use
MH  - Recovery of Function
MH  - Simendan
MH  - Stroke Volume/drug effects
MH  - Systole/*drug effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Turkey
MH  - Ventricular Dysfunction, Left/blood/*diagnostic imaging/*drug 
      therapy/physiopathology
MH  - Ventricular Function, Left/*drug effects
EDAT- 2014/05/23 06:00
MHDA- 2016/08/03 06:00
CRDT- 2014/05/22 06:00
PHST- 2014/03/05 00:00 [received]
PHST- 2014/04/23 00:00 [accepted]
PHST- 2014/04/01 00:00 [revised]
PHST- 2014/05/22 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2016/08/03 06:00 [medline]
AID - VM/OJS/J/37512 [pii]
AID - 10.5603/CJ.a2014.0044 [doi]
PST - ppublish
SO  - Cardiol J. 2015;22(1):87-93. doi: 10.5603/CJ.a2014.0044. Epub 2014 May 20.